"Pelago Bioscience offers exceptional technical expertise in all aspects of target deconvolution using CETSA – including study design, sample preparation, LC-MS data acquisition, and statistical processing. Our collaboration always proceeded effectively due to Pelago Bioscience's responsiveness, scientific commitment, and dedication to clients resulting in delivery of impactful scientific results."

Benjamin Fontaine, Scientist

LifeMine Therapeutics

"Using our world leading expertise in CETSA we have created a faster and more efficient drug discovery process. We take great pride in knowing our customers are bringing new medicines to market more quickly thanks to our help."

Michael Dabrowski, CEO and Co-founder

Pelago Bioscience

"Chemoproteomics is like taking a watch to pieces and counting the cogs – it doesn't tell you which cogs drive which process and how the wider system works. This is why using CETSA can add so much value to your target identification studies."

Pär Nordlund, Professor and Inventor of CETSA

Karolinska Institute

"CETSA data is a keystone in our SAR analysis, and by assessing cellular target engagement of our compounds across multiple cell lines we gain confidence in our project prioritizations."

Peter Joyce, CEO and Co-Founder

Grey Wolf Therapeutics

"Our small molecule drug discovery project was seeking a robust assay allowing to screen against the target of interest expressed in its natural cellular environment. Pelago Bioscience's expertise in drug discovery projects, specifically in the CETSA platform and high throughput screens was the key to achieving our goals. We found Pelago's team to be professional, knowledgeable, flexible and dedicated. We highly recommend Pelago Bioscience for drug discovery projects."

Po-Shun Lee, Chief Medical Officer

Generian